Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05741021 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 84 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 24, 2023 |
| clinicaltrials |
| NCT05738317 | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | unknown | Phase 2 | 45 | Xiaorong DongOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | unknown | Phase 2 | 114 | Peking Union Medical College HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05257512 | Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 150 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(FOCUS-A) | unknown | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05662813 | Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy | unknown | Phase 2 | 55 | West China HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | unknown | Phase 2 | 28 | Tiziana Life Sciences LTDINDUSTRY | 0 | Dec 15, 2022 | clinicaltrials |
| NCT03574402 | Phase II Umbrella Study Directed by Next Generation Sequencing(TRUMP) | unknown | Phase 2 | 400 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603013 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | unknown | Phase 2 | 45 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05574998 | First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial(FTANLCNDG) | unknown | Phase 2 | 100 | Qianfoshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05548348 | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation | unknown | Phase 2 | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05534113 | Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC | unknown | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05529355 | Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 45 | Anhui Chest HospitalOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507606 | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05380024 | A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 10 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | unknown | Phase 2 | 42 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05117658 | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 83 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05485350 | Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 32 | Peking University Third HospitalOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05458726 | Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | unknown | Phase 2 | 80 | Peking Union Medical CollegeOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05472467 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer(IMCORT-2) | unknown | Phase 2 | 35 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | unknown | Phase 2 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05460195 | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | unknown | Phase 2 | 42 | Shanghai Chest HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04459611 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）(neoSCORE) | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib(breakthrough) | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05448781 | Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | unknown | Phase 2 | 38 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05414630 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | unknown | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2023source: clinicaltrials